{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:50:30Z","timestamp":1791186630785,"version":"4.1.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s12035-008-8031-2","type":"journal-article","created":{"date-parts":[[2008,6,25]],"date-time":"2008-06-25T14:46:03Z","timestamp":1214405163000},"page":"171-186","source":"Crossref","is-referenced-by-count":101,"title":["Therapeutic Strategies for Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Donna M.","family":"Barten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Albright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,26]]},"reference":[{"key":"8031_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement 3:186\u2013191","journal-title":"Alzheimers Dement"},{"key":"8031_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1749-6632.2000.tb06942.x","volume":"920","author":"E Giacobini","year":"2000","unstructured":"Giacobini E (2000) Cholinesterase inhibitors stabilize Alzheimer\u2019s disease. Ann NY Acad Sci 920:321\u2013327","journal-title":"Ann NY Acad Sci"},{"key":"8031_CR3","unstructured":"Alzheimer\u2019s Assn (2007) Alzheimer\u2019s disease facts and figures. www.alz.org\/alzheimers_disease_facts_figures.asp"},{"key":"8031_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0891988706291079","volume":"19","author":"RD Terry","year":"2006","unstructured":"Terry RD (2006) Alzheimer\u2019s disease and the aging brain. J Geriatr Psychiatry Neurol 19:125\u2013128","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"8031_CR5","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0197-4580(97)00070-5","volume":"18","author":"JM Powers","year":"1997","unstructured":"Powers JM (1997) Diagnostic criteria for the neuropathologic assessment of Alzheimer\u2019s disease. Neurobiol Aging 18:S53\u2013S54","journal-title":"Neurobiol Aging"},{"key":"8031_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/JAD-1998-1202","volume":"1","author":"AM Kazee","year":"1998","unstructured":"Kazee AM, Johnson EM (1998) Alzheimer\u2019s disease pathology in non-demented elderly. J Alzheimers Dis 1:81\u201389","journal-title":"J Alzheimers Dis"},{"key":"8031_CR7","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1212\/WNL.42.9.1681","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer\u2019s disease. Neurology 42:1681\u20131688","journal-title":"Neurology"},{"key":"8031_CR8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00002512-200724020-00007","volume":"24","author":"RA Hansen","year":"2007","unstructured":"Hansen RA, Gartlehner G, Lohr KN, Kaufer DI (2007) Functional outcomes of drug treatment in Alzheimer\u2019s disease: a systematic review and meta-analysis. Drugs Aging 24:155\u2013167","journal-title":"Drugs Aging"},{"key":"8031_CR9","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/bi060799c","volume":"45","author":"MS Wolfe","year":"2006","unstructured":"Wolfe MS (2006) The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45:7931\u20137939","journal-title":"Biochemistry"},{"key":"8031_CR10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ (2001) Alzheimer\u2019s disease: genes, proteins, and therapy. Physiol Rev 81:741\u2013766","journal-title":"Physiol Rev"},{"key":"8031_CR11","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.96.9.5274","volume":"96","author":"RB Knowles","year":"1999","unstructured":"Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT (1999) Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer\u2019s disease. Proc Natl Acad Sci USA 96:5274\u20135279","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature06616","volume":"451","author":"M Meyer-Luehmann","year":"2008","unstructured":"Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer\u2019s disease. Nature 451:720\u2013724","journal-title":"Nature"},{"key":"8031_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.neuro.26.010302.081142","volume":"26","author":"B Caughey","year":"2003","unstructured":"Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267\u2013298","journal-title":"Annu Rev Neurosci"},{"key":"8031_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","volume":"8","author":"JP Cleary","year":"2005","unstructured":"Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79\u201384","journal-title":"Nat Neurosci"},{"key":"8031_CR15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jnr.10776","volume":"74","author":"CA Wilson","year":"2003","unstructured":"Wilson CA, Doms RW, Lee VM (2003) Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. J Neurosci Res 74:361\u2013369","journal-title":"J Neurosci Res"},{"key":"8031_CR16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535\u2013539","journal-title":"Nature"},{"key":"8031_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0006-8993(01)03058-X","volume":"924","author":"HW Wang","year":"2002","unstructured":"Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1\u201342) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133\u2013140","journal-title":"Brain Res"},{"key":"8031_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","volume":"440","author":"S Lesne","year":"2006","unstructured":"Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352\u2013357","journal-title":"Nature"},{"key":"8031_CR19","doi-asserted-by":"crossref","first-page":"23818","DOI":"10.1074\/jbc.M701078200","volume":"282","author":"IH Cheng","year":"2007","unstructured":"Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating Amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282:23818\u201323828","journal-title":"J Biol Chem"},{"key":"8031_CR20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ana.21051","volume":"60","author":"M Townsend","year":"2006","unstructured":"Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O\u2019Hare E, Walsh DM, Selkoe DJ (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Annal Neurol 60:668\u2013676","journal-title":"Annal Neurol"},{"key":"8031_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00126839-200607020-00003","volume":"7","author":"DM Barten","year":"2006","unstructured":"Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF (2006) Gamma-secretase inhibitors for Alzheimer\u2019s disease: balancing efficacy and toxicity. Drugs R D 7:87\u201397","journal-title":"Drugs R D"},{"key":"8031_CR22","first-page":"35","volume":"6","author":"SJ Pollack","year":"2005","unstructured":"Pollack SJ, Lewis H (2005) Secretase inhibitors for Alzheimer\u2019s disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 6:35\u201347","journal-title":"Curr Opin Investig Drugs"},{"key":"8031_CR23","doi-asserted-by":"crossref","first-page":"46107","DOI":"10.1074\/jbc.M307757200","volume":"278","author":"GH Searfoss","year":"2003","unstructured":"Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278:46107\u201346116","journal-title":"J Biol Chem"},{"key":"8031_CR24","doi-asserted-by":"crossref","first-page":"12876","DOI":"10.1074\/jbc.M311652200","volume":"279","author":"GT Wong","year":"2004","unstructured":"Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876\u201312882","journal-title":"J Biol Chem"},{"key":"8031_CR25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/toxsci\/kfh254","volume":"82","author":"J Milano","year":"2004","unstructured":"Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ (2004) Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82:341\u2013358","journal-title":"Toxicol Sci"},{"key":"8031_CR26","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1523\/JNEUROSCI.2693-05.2005","volume":"25","author":"TA Comery","year":"2005","unstructured":"Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer\u2019s disease. J Neurosci 25:8898\u20138902","journal-title":"J Neurosci"},{"key":"8031_CR27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.wnf.0000167360.27670.29","volume":"28","author":"E Siemers","year":"2005","unstructured":"Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126\u2013132","journal-title":"Clin Neuropharmacol"},{"key":"8031_CR28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.WNL.0000198762.41312.E1","volume":"66","author":"ER Siemers","year":"2006","unstructured":"Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66:602\u2013604","journal-title":"Neurology"},{"key":"8031_CR29","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jalz.2006.05.310","volume":"2","author":"L Rosen","year":"2006","unstructured":"Rosen L, Stone J, Plump A, Yuan J, Harrison T, Flynn M, Dallob A, Matthews C, Stevenson D, Schmidt D, Palmieri T, Leibowitz M, Jhee S, Ereshefsky L, Salomon R, Winchell G, Shearman M, Murphy M, Gottesdiener K (2006) The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimers Dement 2:S79","journal-title":"Alzheimers Dement"},{"key":"8031_CR30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tips.2003.12.004","volume":"25","author":"M Citron","year":"2004","unstructured":"Citron M (2004) Beta-secretase inhibition for the treatment of Alzheimer\u2019s disease\u2013promise and challenge. Trends Pharmacol Sci 25:92\u201397","journal-title":"Trends Pharmacol Sci"},{"key":"8031_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Y Luo","year":"2001","unstructured":"Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer\u2019s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231\u2013232","journal-title":"Nat Neurosci"},{"key":"8031_CR32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1460-9568.2005.04551.x","volume":"23","author":"M Ohno","year":"2006","unstructured":"Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF (2006) Temporal memory deficits in Alzheimer\u2019s mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 23:251\u2013260","journal-title":"Eur J Neurosci"},{"key":"8031_CR33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","volume":"41","author":"M Ohno","year":"2004","unstructured":"Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 Deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer\u2019s disease. Neuron 41:27\u201333","journal-title":"Neuron"},{"key":"8031_CR34","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang H-C, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee H-K, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-b amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693\u201311709","journal-title":"J Neurosci"},{"key":"8031_CR35","doi-asserted-by":"crossref","first-page":"30797","DOI":"10.1074\/jbc.M505249200","volume":"280","author":"D Dominguez","year":"2005","unstructured":"Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D\u2019Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280:30797\u201330806","journal-title":"J Biol Chem"},{"key":"8031_CR36","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/nn1797","volume":"9","author":"X Hu","year":"2006","unstructured":"Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9:1520\u20131525","journal-title":"Nat Neurosci"},{"key":"8031_CR37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1126\/science.1132341","volume":"314","author":"M Willem","year":"2006","unstructured":"Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the b-secretase BACE1. Science 314:664\u2013666","journal-title":"Science"},{"key":"8031_CR38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1124\/jpet.107.130039","volume":"324","author":"S Sankaranarayanan","year":"2008","unstructured":"Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 324:957\u2013969","journal-title":"J Pharmacol Exp Ther"},{"key":"8031_CR39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1471-4159.2005.03576.x","volume":"96","author":"M Asai","year":"2006","unstructured":"Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, Hashimoto Y, Maruyama K, Tanuma S-i, Kiso Y, Ishiura S (2006) The novel b-secretase inhibitor KMI-429 reduces amyloid b peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 96:533\u2013540","journal-title":"J Neurochem"},{"key":"8031_CR40","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/jm061234h","volume":"49","author":"SJ Stachel","year":"2006","unstructured":"Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, Jin L, Ellis J, Holloway MK, Munshi S, Allison T, Hazuda D, Simon AJ, Graham SL, Vacca JP (2006) Macrocyclic inhibitors of b-secretase: functional activity in an animal model. [Erratum to document cited in CA145:465146]. J Med Chem 49:7252","journal-title":"J Med Chem"},{"key":"8031_CR41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212\u2013216","journal-title":"Nature"},{"key":"8031_CR42","doi-asserted-by":"crossref","first-page":"31279","DOI":"10.1074\/jbc.M605051200","volume":"281","author":"EE Clarke","year":"2006","unstructured":"Clarke EE, Churcher I, Ellis S, Wrigley JD, Lewis HD, Harrison T, Shearman MS, Beher D (2006) Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes. J Biol Chem 281:31279\u201331289","journal-title":"J Biol Chem"},{"key":"8031_CR43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000095270","volume":"3","author":"E Czirr","year":"2006","unstructured":"Czirr E, Weggen S (2006) Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neuro-degenerative diseases 3:298\u2013304","journal-title":"Neuro-degenerative diseases"},{"key":"8031_CR44","first-page":"121","volume":"10","author":"H Geerts","year":"2007","unstructured":"Geerts H (2007) Drug evaluation: (R)-flurbiprofen\u2014an enantiomer of flurbiprofen for the treatment of Alzheimer\u2019s disease. IDrugs 10:121\u2013133","journal-title":"IDrugs"},{"key":"8031_CR45","first-page":"392","volume":"10","author":"D Pissarnitski","year":"2007","unstructured":"Pissarnitski D (2007) Advances in gamma-secretase modulation. Curr Opin Drug Discov Dev 10:392\u2013402","journal-title":"Curr Opin Drug Discov Dev"},{"key":"8031_CR46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P (2007) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28:537\u2013547","journal-title":"Neurobiol Aging"},{"key":"8031_CR47","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","volume":"67","author":"PS Aisen","year":"2006","unstructured":"Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D (2006) A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67:1757\u20131763","journal-title":"Neurology"},{"key":"8031_CR48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000094773","volume":"3","author":"MO Kwon","year":"2006","unstructured":"Kwon MO, Herrling P (2006) List of drugs in development for neurodegenerative diseases. Update June 2006. Neurodegener Dis 3:148\u2013186","journal-title":"Neurodegener Dis"},{"key":"8031_CR49","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1073\/pnas.122249699","volume":"99","author":"AI Bush","year":"2002","unstructured":"Bush AI, Tanzi RE (2002) The galvanization of beta-amyloid in Alzheimer\u2019s disease. Proc Natl Acad Sci USA 99:7317\u20137319","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR50","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","volume":"30","author":"RA Cherny","year":"2001","unstructured":"Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer\u2019s disease transgenic mice. Neuron 30:665\u2013676","journal-title":"Neuron"},{"key":"8031_CR51","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"CW Ritchie","year":"2003","unstructured":"Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685\u20131691","journal-title":"Arch Neurol"},{"key":"8031_CR52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1358\/dnp.2006.19.8.1021492","volume":"19","author":"PJ Crouch","year":"2006","unstructured":"Crouch PJ, Barnham KJ, Bush AI, White AR (2006) Therapeutic treatments for Alzheimer\u2019s disease based on metal bioavailability. Drug News Perspect 19:469\u2013474","journal-title":"Drug News Perspect"},{"key":"8031_CR53","doi-asserted-by":"crossref","first-page":"18495","DOI":"10.1074\/jbc.M906994199","volume":"275","author":"J McLaurin","year":"2000","unstructured":"McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE (2000) Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem 275:18495\u201318502","journal-title":"J Biol Chem"},{"key":"8031_CR54","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm1423","volume":"12","author":"J McLaurin","year":"2006","unstructured":"McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801\u2013808","journal-title":"Nat Med"},{"key":"8031_CR55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/156802607779318262","volume":"7","author":"LD Estrada","year":"2007","unstructured":"Estrada LD, Soto C (2007) Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7:115\u2013126","journal-title":"Curr Top Med Chem"},{"key":"8031_CR56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.emboj.7601953","volume":"27","author":"IC Martins","year":"2008","unstructured":"Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D\u2019Hooge R, De Strooper B, Schymkowitz J, Rousseau F (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27:224\u2013233","journal-title":"EMBO J"},{"key":"8031_CR57","first-page":"605","volume":"43","author":"RE Tanzi","year":"2004","unstructured":"Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer\u2019s Abeta peptide: the many roads to perdition. Neuron 43:605\u2013608","journal-title":"Neuron"},{"key":"8031_CR58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/BST0330553","volume":"33","author":"MN Pangalos","year":"2005","unstructured":"Pangalos MN, Jacobsen SJ, Reinhart PH (2005) Disease modifying strategies for the treatment of Alzheimer\u2019s disease targeted at modulating levels of the beta-amyloid peptide. Biochem Soc Trans 33:553\u2013558","journal-title":"Biochem Soc Trans"},{"key":"8031_CR59","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nm1206","volume":"11","author":"T Saito","year":"2005","unstructured":"Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Suemoto T, Higuchi M, Saido TC (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11:434\u2013439","journal-title":"Nat Med"},{"key":"8031_CR60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173\u2013177","journal-title":"Nature"},{"key":"8031_CR61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","journal-title":"Neurology"},{"key":"8031_CR62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer\u2019s disease. Brain Pathol 14:11\u201320","journal-title":"Brain Pathol"},{"key":"8031_CR63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","volume":"64","author":"E Masliah","year":"2005","unstructured":"Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129\u2013131","journal-title":"Neurology"},{"key":"8031_CR64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448\u2013452","journal-title":"Nat Med"},{"key":"8031_CR65","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1073\/pnas.0506209103","volume":"103","author":"A Monsonego","year":"2006","unstructured":"Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL (2006) Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 103:5048\u20135053","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR66","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553\u20131562","journal-title":"Neurology"},{"key":"8031_CR67","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","volume":"64","author":"NC Fox","year":"2005","unstructured":"Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563\u20131572","journal-title":"Neurology"},{"key":"8031_CR68","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916\u2013919","journal-title":"Nat Med"},{"key":"8031_CR69","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci 5:452\u2013457","journal-title":"Nat Neurosci"},{"key":"8031_CR70","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T (2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proc Natl Acad Sci USA 100:2023\u20132028","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR71","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379","journal-title":"Science"},{"key":"8031_CR72","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25:629\u2013636","journal-title":"J Neurosci"},{"key":"8031_CR73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24","journal-title":"J Neuroinflammation"},{"key":"8031_CR74","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurobiolaging.2005.12.003","volume":"28","author":"GJ Burbach","year":"2007","unstructured":"Burbach GJ, Vlachos A, Ghebremedhin E, Del Turco D, Coomaraswamy J, Staufenbiel M, Jucker M, Deller T (2007) Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging 28:202\u2013212","journal-title":"Neurobiol Aging"},{"key":"8031_CR75","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1523\/JNEUROSCI.0695-06.2006","volume":"26","author":"DM Wilcock","year":"2006","unstructured":"Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D (2006) Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26:5340\u20135346","journal-title":"J Neurosci"},{"key":"8031_CR76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5414\/NPP26043","volume":"26","author":"GL Lace","year":"2007","unstructured":"Lace GL, Wharton SB, Ince PG (2007) A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin Neuropathol 26:43\u201358","journal-title":"Clin Neuropathol"},{"key":"8031_CR77","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00401-007-0207-8","volume":"113","author":"B Li","year":"2007","unstructured":"Li B, Chohan MO, Grundke-Iqbal I, Iqbal K (2007) Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol 113:501\u2013511","journal-title":"Acta Neuropathol"},{"key":"8031_CR78","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.tig.2005.09.005","volume":"21","author":"B Dermaut","year":"2005","unstructured":"Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C (2005) Tau is central in the genetic Alzheimer\u2013frontotemporal dementia spectrum. Trends Genet 21:664\u2013672","journal-title":"Trends Genet"},{"key":"8031_CR79","first-page":"437","volume":"3","author":"M Blurton-Jones","year":"2006","unstructured":"Blurton-Jones M, Laferla FM (2006) Pathways by which Abeta facilitates tau pathology. CurrAlzheimer Res 3:437\u2013448","journal-title":"CurrAlzheimer Res"},{"key":"8031_CR80","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","volume":"293","author":"J Lewis","year":"2001","unstructured":"Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487\u20131491","journal-title":"Science"},{"key":"8031_CR81","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2353\/ajpath.2007.070403","volume":"171","author":"T Bolmont","year":"2007","unstructured":"Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP \u00d7 Tau transgenic mice. Am J Pathol 171:2012\u20132020","journal-title":"Am J Pathol"},{"key":"8031_CR82","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","volume":"293","author":"J Gotz","year":"2001","unstructured":"Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491\u20131495","journal-title":"Science"},{"key":"8031_CR83","unstructured":"De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio E.H., Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL (2007) Alzheimer\u2019s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging, epub April 9, 2007"},{"key":"8031_CR84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","volume":"43","author":"S Oddo","year":"2004","unstructured":"Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321\u2013332","journal-title":"Neuron"},{"key":"8031_CR85","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","volume":"316","author":"ED Roberson","year":"2007","unstructured":"Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model. Science 316:750\u2013754","journal-title":"Science"},{"key":"8031_CR86","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2005.02.008","volume":"11","author":"HG Lee","year":"2005","unstructured":"Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA (2005) Tau phosphorylation in Alzheimer\u2019s disease: pathogen or protector? Trends Mol Med 11:164\u2013169","journal-title":"Trends Mol Med"},{"key":"8031_CR87","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005072-199902000-00008","volume":"58","author":"R Morsch","year":"1999","unstructured":"Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58:188\u2013197","journal-title":"J Neuropathol Exp Neurol"},{"key":"8031_CR88","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1523\/JNEUROSCI.4637-04.2005","volume":"25","author":"C Andorfer","year":"2005","unstructured":"Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25:5446\u20135454","journal-title":"J Neurosci"},{"key":"8031_CR89","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santacruz","year":"2005","unstructured":"Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476\u2013481","journal-title":"Science"},{"key":"8031_CR90","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1523\/JNEUROSCI.0587-07.2007","volume":"27","author":"Z Berger","year":"2007","unstructured":"Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27:3650\u20133662","journal-title":"J Neurosci"},{"key":"8031_CR91","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/bi061359o","volume":"46","author":"S Maeda","year":"2007","unstructured":"Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46:3856\u20133861","journal-title":"Biochemistry"},{"key":"8031_CR92","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","volume":"1","author":"DM Skovronsky","year":"2006","unstructured":"Skovronsky DM, Lee VM-Y, Trojanowski JQ (2006) Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis 1:151\u2013170","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"8031_CR93","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156802606776743057","volume":"6","author":"I Churcher","year":"2006","unstructured":"Churcher I (2006) Tau therapeutic strategies for the treatment of Alzheimer\u2019s disease. Curr Top Med Chem 6:579\u2013595","journal-title":"Curr Top Med Chem"},{"key":"8031_CR94","first-page":"464","volume":"6","author":"MP Mazanetz","year":"2007","unstructured":"Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev 6:464\u2013479","journal-title":"Nat Rev"},{"key":"8031_CR95","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/156720506779025279","volume":"3","author":"K Mi","year":"2006","unstructured":"Mi K, Johnson GV (2006) The role of tau phosphorylation in the pathogenesis of Alzheimer\u2019s disease. Curr Alzheimer Res 3:449\u2013463","journal-title":"Curr Alzheimer Res"},{"key":"8031_CR96","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.neurobiolaging.2005.06.010","volume":"27","author":"T Engel","year":"2006","unstructured":"Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F (2006) Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 27:1258\u20131268","journal-title":"Neurobiol Aging"},{"key":"8031_CR97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0896-6273(02)00706-7","volume":"34","author":"GR Jackson","year":"2002","unstructured":"Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34:509\u2013519","journal-title":"Neuron"},{"key":"8031_CR98","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jnr.20734","volume":"83","author":"QL Ma","year":"2006","unstructured":"Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM (2006) Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83:374\u2013384","journal-title":"J Neurosci Res"},{"key":"8031_CR99","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","volume":"102","author":"W Noble","year":"2005","unstructured":"Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, Lafrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990\u20136995","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00401-005-1087-4","volume":"110","author":"H Nakashima","year":"2005","unstructured":"Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S, Hamamura T, Trojanowski JQ, Lee VM, Kuroda S (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110:547\u2013556","journal-title":"Acta Neuropathol"},{"key":"8031_CR101","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1523\/JNEUROSCI.4321-06.2007","volume":"27","author":"E Rockenstein","year":"2007","unstructured":"Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer\u2019s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981\u20131991","journal-title":"J Neurosci"},{"key":"8031_CR102","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","volume":"32","author":"RS Jope","year":"2007","unstructured":"Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577\u2013595","journal-title":"Neurochem Res"},{"key":"8031_CR103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1460-9568.2006.05245.x","volume":"25","author":"C Hooper","year":"2007","unstructured":"Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF, Avila J, Lucas JJ, Giese KP, Stephenson J, Lovestone S (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25:81\u201386","journal-title":"Eur J Neurosci"},{"key":"8031_CR104","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2007.01.029","volume":"53","author":"S Peineau","year":"2007","unstructured":"Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53:703\u2013717","journal-title":"Neuron"},{"key":"8031_CR105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1254\/jphs.CRJ05009X","volume":"99","author":"A Wada","year":"2005","unstructured":"Wada A, Yokoo H, Yanagita T, Kobayashi H (2005) Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 99:307\u2013321","journal-title":"J Pharmacol Sci"},{"key":"8031_CR106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10540-005-2893-6","volume":"25","author":"A Caricasole","year":"2005","unstructured":"Caricasole A, Bakker A, Copani A, Nicoletti F, Gaviraghi G, Terstappen GC (2005) Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 25:309\u2013327","journal-title":"Biosci Rep"},{"key":"8031_CR107","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.bbrc.2005.07.041","volume":"334","author":"A Shakoori","year":"2005","unstructured":"Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T (2005) Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334:1365\u20131373","journal-title":"Biochem Biophys Res Commun"},{"key":"8031_CR108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.surg.2006.12.005","volume":"141","author":"A Kappes","year":"2007","unstructured":"Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H (2007) Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery 141:161\u2013165, discussion 165","journal-title":"Surgery"},{"key":"8031_CR109","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.cr.7310078","volume":"16","author":"Q Cao","year":"2006","unstructured":"Cao Q, Lu X, Feng YJ (2006) Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16:671\u2013677","journal-title":"Cell Res"},{"key":"8031_CR110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1471-4159.2004.02422.x","volume":"89","author":"RV Bhat","year":"2004","unstructured":"Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89:1313\u20131317","journal-title":"J Neurochem"},{"key":"8031_CR111","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tips.2004.07.006","volume":"25","author":"L Meijer","year":"2004","unstructured":"Meijer L, Flajolet M, Greengard P (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25:471\u2013480","journal-title":"Trends Pharmacol Sci"},{"key":"8031_CR112","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/13543784.16.8.1183","volume":"16","author":"AJ Stewart","year":"2007","unstructured":"Stewart AJ, Fox A, Morimoto BH, Gozes I (2007) Looking for novel ways to treat the hallmarks of Alzheimer\u2019s disease. Expert Opin Investig Drugs 16:1183\u20131196","journal-title":"Expert Opin Investig Drugs"},{"key":"8031_CR113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-2007-12105","volume":"12","author":"E Giacobini","year":"2007","unstructured":"Giacobini E, Becker RE (2007) One hundred years after the discovery of Alzheimer\u2019s disease. A turning point for therapy? J Alzheimers Dis 12:37\u201352","journal-title":"J Alzheimers Dis"},{"key":"8031_CR114","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/1533317506297573","volume":"21","author":"N Briefs","year":"2007","unstructured":"Briefs N (2007) New Azlheimer\u2019s clinical trials to be undertaken by NIA nationwide consortium. Am J Alzheimers Dis Other Dement 21:460\u2013462","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"8031_CR115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/jnr.21232","volume":"85","author":"ML Steinhilb","year":"2007","unstructured":"Steinhilb ML, Dias-Santagata D, Mulkearns EE, Shulman JM, Biernat J, Mandelkow EM, Feany MB (2007) S\/P and T\/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res 85:1271\u20131278","journal-title":"J Neurosci Res"},{"key":"8031_CR116","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cne.10186","volume":"446","author":"F Bian","year":"2002","unstructured":"Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, Pack A, Wang KK, Walker LC (2002) Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 446:257\u2013266","journal-title":"J Comp Neurol"},{"key":"8031_CR117","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1073\/pnas.040577797","volume":"97","author":"MK Ahlijanian","year":"2000","unstructured":"Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97:2910\u20132915","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR118","doi-asserted-by":"crossref","first-page":"25457","DOI":"10.1074\/jbc.M603469200","volume":"281","author":"F Plattner","year":"2006","unstructured":"Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281:25457\u201325465","journal-title":"J Biol Chem"},{"key":"8031_CR119","doi-asserted-by":"crossref","first-page":"10633","DOI":"10.1523\/JNEUROSCI.23-33-10633.2003","volume":"23","author":"JL Hallows","year":"2003","unstructured":"Hallows JL, Chen K, DePinho RA, Vincent I (2003) Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 23:10633\u201310644","journal-title":"J Neurosci"},{"key":"8031_CR120","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1523\/JNEUROSCI.5245-07.2008","volume":"28","author":"Y Wen","year":"2008","unstructured":"Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28:2624\u20132632","journal-title":"J Neurosci"},{"key":"8031_CR121","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nn1914","volume":"10","author":"AH Hawasli","year":"2007","unstructured":"Hawasli AH, Benavides DR, Nguyen C, Kansy JW, Hayashi K, Chambon P, Greengard P, Powell CM, Cooper DC, Bibb JA (2007) Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci 10:880\u2013886","journal-title":"Nat Neurosci"},{"key":"8031_CR122","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.chembiol.2005.05.011","volume":"12","author":"JS Ahn","year":"2005","unstructured":"Ahn JS, Radhakrishnan ML, Mapelli M, Choi S, Tidor B, Cuny GD, Musacchio A, Yeh LA, Kosik KS (2005) Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol 12:811\u2013823","journal-title":"Chem Biol"},{"key":"8031_CR123","doi-asserted-by":"crossref","first-page":"9673","DOI":"10.1073\/pnas.0602913103","volume":"103","author":"S Corre Le","year":"2006","unstructured":"Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 103:9673\u20139678","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1567205053585927","volume":"2","author":"CA Dickey","year":"2005","unstructured":"Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels\u2014proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2:231\u2013238","journal-title":"Curr Alzheimer Res"},{"key":"8031_CR125","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1172\/JCI29715","volume":"117","author":"CA Dickey","year":"2007","unstructured":"Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117:648\u2013658","journal-title":"J Clin Invest"},{"key":"8031_CR126","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1073\/pnas.0701055104","volume":"104","author":"W Luo","year":"2007","unstructured":"Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G (2007) Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 104:9511\u20139516","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR127","first-page":"6","volume":"1","author":"CA Dickey","year":"2006","unstructured":"Dickey CA, Ash P, Klosak N, Lee WC, Petrucelli L, Hutton M, Eckman CB (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neuropharmacol 1:6","journal-title":"Mol Neuropharmacol"},{"key":"8031_CR128","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"AA Asuni","year":"2007","unstructured":"Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115\u20139129","journal-title":"J Neurosci"},{"key":"8031_CR129","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.tins.2006.07.003","volume":"29","author":"RA Nixon","year":"2006","unstructured":"Nixon RA (2006) Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci 29:528\u2013535","journal-title":"Trends Neurosci"},{"key":"8031_CR130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.mam.2006.08.009","volume":"27","author":"B Boland","year":"2006","unstructured":"Boland B, Nixon RA (2006) Neuronal macroautophagy: from development to degeneration. Mol Aspects Med 27:503\u2013519","journal-title":"Mol Aspects Med"},{"key":"8031_CR131","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4161\/auto.2729","volume":"2","author":"D Butler","year":"2006","unstructured":"Butler D, Nixon RA, Bahr BA (2006) Potential compensatory responses through autophagic\/lysosomal pathways in neurodegenerative diseases. Autophagy 2:234\u2013237","journal-title":"Autophagy"},{"key":"8031_CR132","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nchembio883","volume":"3","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O\u2019Kane CJ, Schreiber SL, Rubinsztein DC (2007) Small molecules enhance autophagy and reduce toxicity in Huntington\u2019s disease models. Nat Chem Biol 3:331\u2013338","journal-title":"Nat Chem Biol"},{"key":"8031_CR133","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0006-8993(95)00537-Z","volume":"689","author":"K Furukawa","year":"1995","unstructured":"Furukawa K, Mattson MP (1995) Taxol stabilizes [Ca2+]i and protects hippocampal neurons against excitotoxicity. Brain Res 689:141\u2013146","journal-title":"Brain Res"},{"key":"8031_CR134","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2007.01.053","volume":"562","author":"D Butler","year":"2007","unstructured":"Butler D, Bendiske J, Michaelis ML, Karanian DA, Bahr BA (2007) Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 562:20\u201327","journal-title":"Eur J Pharmacol"},{"key":"8031_CR135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/jpet.104.074450","volume":"312","author":"ML Michaelis","year":"2005","unstructured":"Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI, Himes RH, Audus KL, Georg GI (2005) {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 312:659\u2013668","journal-title":"J Pharmacol Exp Ther"},{"key":"8031_CR136","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","volume":"102","author":"B Zhang","year":"2005","unstructured":"Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227\u2013231","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR137","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1006343818656","volume":"45","author":"TJ Postma","year":"1999","unstructured":"Postma TJ, Hoekman K, van Riel JMGH, Heimans JJ, Vermorken JB (1999) Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cispatin in patients with advanced ovarian cancer. J Neuro-oncol 45:241\u2013246","journal-title":"J Neuro-oncol"},{"key":"8031_CR138","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14656566.6.5.683","volume":"6","author":"JQ Trojanowski","year":"2005","unstructured":"Trojanowski JQ, Smith AB, Huryn D, Lee VM (2005) Microtubule-stabilising drugs for therapy of Alzheimer\u2019s disease and other neurodegenerative disorders with axonal transport impairments. Expert Opin Pharmacother 6:683\u2013686","journal-title":"Expert Opin Pharmacother"},{"key":"8031_CR139","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2007.01.004","volume":"114","author":"I Gozes","year":"2007","unstructured":"Gozes I (2007) Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther 114:146\u2013154","journal-title":"Pharmacol Ther"},{"key":"8031_CR140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","volume":"325","author":"Y Matsuoka","year":"2008","unstructured":"Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer\u2019s disease. J Pharmacol Exp Ther 325:146\u2013153","journal-title":"J Pharmacol Exp Ther"},{"key":"8031_CR141","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/156720505774330528","volume":"2","author":"AK Stark","year":"2005","unstructured":"Stark AK, Pelvig DP, Jorgensen AM, Andersen BB, Pakkenberg B (2005) Measuring morphological and cellular changes in Alzheimer\u2019s dementia: a review emphasizing stereology. Curr Alzheimer Res 2:449\u2013481","journal-title":"Curr Alzheimer Res"},{"key":"8031_CR142","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298:789\u2013791","journal-title":"Science"},{"key":"8031_CR143","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1515\/REVNEURO.2006.17.6.635","volume":"17","author":"E Elliott","year":"2006","unstructured":"Elliott E, Ginzburg I (2006) The role of neurotrophins and insulin on tau pathology in Alzheimer\u2019s disease. Rev Neurosci 17:635\u2013642","journal-title":"Rev Neurosci"},{"key":"8031_CR144","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10571-006-9112-2","volume":"26","author":"S Capsoni","year":"2006","unstructured":"Capsoni S, Cattaneo A (2006) On the molecular basis linking nerve growth factor (NGF) to Alzheimer\u2019s disease. Cell Mol Neurobiol 26:619\u2013633","journal-title":"Cell Mol Neurobiol"},{"key":"8031_CR145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1567205053585819","volume":"2","author":"FM Longo","year":"2005","unstructured":"Longo FM, Massa SM (2005) Neurotrophin receptor-based strategies for Alzheimer\u2019s disease. Curr Alzheimer Res 2:167\u2013169","journal-title":"Curr Alzheimer Res"},{"key":"8031_CR146","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/dneu.20510","volume":"67","author":"MH Tuszynski","year":"2007","unstructured":"Tuszynski MH (2007) Nerve growth factor gene delivery: animal models to clinical trials. Dev Neurobiol 67:1204\u20131215","journal-title":"Dev Neurobiol"},{"key":"8031_CR147","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/156720506777632817","volume":"3","author":"RD Brinton","year":"2006","unstructured":"Brinton RD, Wang JM (2006) Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer\u2019s disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res 3:185\u2013190","journal-title":"Curr Alzheimer Res"},{"key":"8031_CR148","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/156720507783018316","volume":"4","author":"FM Longo","year":"2007","unstructured":"Longo FM, Yang T, Knowles JK, Xie Y, Moore LA, Massa SM (2007) Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer\u2019s disease mechanisms. Curr Alzheimer Res 4:503\u2013506","journal-title":"Curr Alzheimer Res"},{"key":"8031_CR149","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.wad.0000213866.86934.7e","volume":"20","author":"S Craft","year":"2006","unstructured":"Craft S (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20:298\u2013301","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"8031_CR150","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db07-0171","volume":"56","author":"ZG Li","year":"2007","unstructured":"Li ZG, Zhang W, Sima AA (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56:1817\u20131824","journal-title":"Diabetes"},{"key":"8031_CR151","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jalz.2005.12.001","volume":"2","author":"AD Roses","year":"2006","unstructured":"Roses AD, Saunders AM (2006) Perspective on a pathogenesis and treatment of Alzheimer\u2019s disease. Alzheimers Dement 2:59\u201370","journal-title":"Alzheimers Dement"},{"key":"8031_CR152","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2006.11.017","volume":"184","author":"MT Heneka","year":"2007","unstructured":"Heneka MT, O\u2019Banion MK (2007) Inflammatory processes in Alzheimer\u2019s disease. J Neuroimmunol 184:69\u201391","journal-title":"J Neuroimmunol"},{"key":"8031_CR153","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1568007054038201","volume":"4","author":"JJ Hoozemans","year":"2005","unstructured":"Hoozemans JJ, O\u2019Banion MK (2005) The role of COX-1 and COX-2 in Alzheimer\u2019s disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 4:307\u2013315","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"8031_CR154","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2174\/138161206775474215","volume":"12","author":"GE Ringheim","year":"2006","unstructured":"Ringheim GE, Szczepanik AM (2006) Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer\u2019s disease. Curr Pharm Des 12:719\u2013738","journal-title":"Curr Pharm Des"},{"key":"8031_CR155","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/glia.20338","volume":"53","author":"TJ Seabrook","year":"2006","unstructured":"Seabrook TJ, Jiang L, Maier M, Lemere CA (2006) Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53:776\u2013782","journal-title":"Glia"},{"key":"8031_CR156","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2007.01.052","volume":"416","author":"A Familian","year":"2007","unstructured":"Familian A, Eikelenboom P, Veerhuis R (2007) Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci Lett 416:87\u201391","journal-title":"Neurosci Lett"},{"key":"8031_CR157","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","volume":"104","author":"N Zelcer","year":"2007","unstructured":"Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P (2007) Attenuation of neuroinflammation and Alzheimer\u2019s disease pathology by liver x receptors. Proc Natl Acad Sci USA 104:10601\u201310606","journal-title":"Proc Natl Acad Sci USA"},{"key":"8031_CR158","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0404.2006.00689.x","volume":"185","author":"DL Sparks","year":"2006","unstructured":"Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P (2006) Statin therapy in Alzheimer\u2019s disease. Acta Neurol Scand 185:78\u201386","journal-title":"Acta Neurol Scand"},{"key":"8031_CR159","unstructured":"Marchalant Y, Cerbai F, Brothers HM, Wenk GL (2007) Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol Aging, epub June 8, 2007"},{"key":"8031_CR160","first-page":"1005","volume":"12","author":"T Wyss-Coray","year":"2006","unstructured":"Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005\u20131015","journal-title":"Nat Med"},{"key":"8031_CR161","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.jnen.0000178444.33972.e0","volume":"64","author":"D Morgan","year":"2005","unstructured":"Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64:743\u2013753","journal-title":"J Neuropathol Exp Neurol"},{"key":"8031_CR162","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337\u2013351","journal-title":"Neuron"},{"key":"8031_CR163","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/138161206775474251","volume":"12","author":"A Huber","year":"2006","unstructured":"Huber A, Stuchbury G, Burkle A, Burnell J, Munch G (2006) Neuroprotective therapies for Alzheimer\u2019s disease. Curr Pharm Des 12:705\u2013717","journal-title":"Curr Pharm Des"},{"key":"8031_CR164","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.pnpbp.2004.12.007","volume":"29","author":"PG Sullivan","year":"2005","unstructured":"Sullivan PG, Brown MR (2005) Mitochondrial aging and dysfunction in Alzheimer\u2019s disease. Prog Neuro-psychopharmacol Biol Psychiatry 29:407\u2013410","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"key":"8031_CR165","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.pneurobio.2007.06.001","volume":"82","author":"S Mandel","year":"2007","unstructured":"Mandel S, Amit T, Bar-Am O, Youdim MB (2007) Iron dysregulation in Alzheimer\u2019s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 82:348\u2013360","journal-title":"Prog Neurobiol"},{"key":"8031_CR166","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-2003-45117","volume":"36","author":"S Kanowski","year":"2003","unstructured":"Kanowski S, Hoerr R (2003) Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 36:297\u2013303","journal-title":"Pharmacopsychiatry"},{"key":"8031_CR167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S104161020600439X","volume":"19","author":"D Ames","year":"2007","unstructured":"Ames D, Ritchie C (2007) Antioxidants and Alzheimer\u2019s disease: time to stop feeding vitamin E to dementia patients? Int Psychogeriatr\/IPA 19:1\u20138","journal-title":"Int Psychogeriatr\/IPA"},{"key":"8031_CR168","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/gps.1857","volume":"23","author":"Y Freund-Levi","year":"2008","unstructured":"Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jonhagen M (2008) Omega-3 supplementation in mild to moderate Alzheimer\u2019s disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23:161\u2013169","journal-title":"Int J Geriatr Psychiatry"},{"key":"8031_CR169","first-page":"160","volume":"5","author":"SA Lipton","year":"2006","unstructured":"Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev 5:160\u2013170","journal-title":"Nat Rev"},{"key":"8031_CR170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00008877-200609000-00007","volume":"17","author":"GL Wenk","year":"2006","unstructured":"Wenk GL, Parsons CG, Danysz W (2006) Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17:411\u2013424","journal-title":"Behav Pharmacol"},{"key":"8031_CR171","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1528-1167.2006.00554.x","volume":"47","author":"JC Amatniek","year":"2006","unstructured":"Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer\u2019s disease. Epilepsia 47:867\u2013872","journal-title":"Epilepsia"},{"key":"8031_CR172","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317\u2013324","journal-title":"JAMA"},{"key":"8031_CR173","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pbb.2006.08.011","volume":"85","author":"PR Zoladz","year":"2006","unstructured":"Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM (2006) Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav 85:298\u2013306","journal-title":"Pharmacol Biochem Behav"},{"key":"8031_CR174","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1074\/jbc.M607483200","volume":"282","author":"FG Felice De","year":"2007","unstructured":"De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590\u201311601","journal-title":"J Biol Chem"},{"key":"8031_CR175","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","volume":"55","author":"JJ Palop","year":"2007","unstructured":"Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer\u2019s disease. Neuron 55:697\u2013711","journal-title":"Neuron"},{"key":"8031_CR176","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature05289","volume":"443","author":"JJ Palop","year":"2006","unstructured":"Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768\u2013773","journal-title":"Nature"},{"key":"8031_CR177","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0301-0082(97)00028-2","volume":"52","author":"P Kasa","year":"1997","unstructured":"Kasa P, Rakonczay Z, Gulya K (1997) The cholinergic system in Alzheimer\u2019s disease. Prog Neurobiol 52:511\u2013535","journal-title":"Prog Neurobiol"},{"issue":"Suppl 1","key":"8031_CR178","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1041610203008688","volume":"14","author":"M Farlow","year":"2002","unstructured":"Farlow M (2002) A clinical overview of cholinesterase inhibitors in Alzheimer\u2019s disease. Int Psychogeriatr\/IPA 14(Suppl 1):93\u2013126","journal-title":"Int Psychogeriatr\/IPA"},{"key":"8031_CR179","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"MA Raskind","year":"2000","unstructured":"Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261\u20132268","journal-title":"Neurology"},{"key":"8031_CR180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/138955707780059817","volume":"7","author":"M Decker","year":"2007","unstructured":"Decker M (2007) Recent advances in the development of hybrid molecules\/designed multiple compounds with antiamnesic properties. Mini Rev Med Chem 7:221\u2013229","journal-title":"Mini Rev Med Chem"},{"key":"8031_CR181","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/13543784.16.7.1087","volume":"16","author":"J Klein","year":"2007","unstructured":"Klein J (2007) Phenserine. Expert Opin Investig Drugs 16:1087\u20131097","journal-title":"Expert Opin Investig Drugs"},{"key":"8031_CR182","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10571-007-9163-z","volume":"28","author":"HY Zhang","year":"2008","unstructured":"Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine a: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28:173\u2013183","journal-title":"Cell Mol Neurobiol"},{"key":"8031_CR183","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","volume":"939","author":"S Bachurin","year":"2001","unstructured":"Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939:425\u2013435","journal-title":"Ann NY Acad Sci"},{"key":"8031_CR184","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1749-6632.2003.tb07541.x","volume":"993","author":"SO Bachurin","year":"2003","unstructured":"Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 993:334\u2013344, discussion 345\u2013339","journal-title":"Ann NY Acad Sci"},{"key":"8031_CR185","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.jalz.2007.04.004","volume":"3","author":"RS Doody","year":"2007","unstructured":"Doody RS, Gavrilova S, Sano M, Thomas R, Aisen P, Bachurin S, Seely L, Hung D (2007) Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer\u2019s disease. Alzheimers Dement 3:S199\u2013S200","journal-title":"Alzheimers Dement"},{"key":"8031_CR186","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.pharmtox.44.101802.121622","volume":"44","author":"J Wess","year":"2004","unstructured":"Wess J (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44:423\u2013450","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"8031_CR187","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1385\/JMN:20:3:349","volume":"20","author":"A Fisher","year":"2003","unstructured":"Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R (2003) M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer\u2019s disease: implications in future therapy. J Mol Neurosci 20:349\u2013356","journal-title":"J Mol Neurosci"},{"key":"8031_CR188","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","volume":"49","author":"A Caccamo","year":"2006","unstructured":"Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49:671\u2013682","journal-title":"Neuron"},{"key":"8031_CR189","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1517\/13543784.9.10.2259","volume":"9","author":"AD Korczyn","year":"2000","unstructured":"Korczyn AD (2000) Muscarinic M(1) agonists in the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs 9:2259\u20132267","journal-title":"Expert Opin Investig Drugs"},{"key":"8031_CR190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9:159\u2013186","journal-title":"CNS Drug Rev"},{"key":"8031_CR191","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bmc.2003.11.005","volume":"12","author":"JW Clader","year":"2004","unstructured":"Clader JW, Billard W, Binch H 3rd, Chen LY, Crosby G Jr, Duffy RA, Ford J, Kozlowski JA, Lachowicz JE, Li S, Liu C, McCombie SW, Vice S, Zhou G, Greenlee WJ (2004) Muscarinic M2 antagonists: anthranilamide derivatives with exceptional selectivity and in vivo activity. Bioorganic Med Chem 12:319\u2013326","journal-title":"Bioorganic Med Chem"},{"key":"8031_CR192","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-827X(01)01102-8","volume":"56","author":"W Greenlee","year":"2001","unstructured":"Greenlee W, Clader J, Asberom T, McCombie S, Ford J, Guzik H, Kozlowski J, Li S, Liu C, Lowe D, Vice S, Zhao H, Zhou G, Billard W, Binch H, Crosby R, Duffy R, Lachowicz J, Coffin V, Watkins R, Ruperto V, Strader C, Taylor L, Cox K (2001) Muscarinic agonists and antagonists in the treatment of Alzheimer\u2019s disease. Farmaco 56:247\u2013250","journal-title":"Farmaco"},{"key":"8031_CR193","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0166-4328(00)00206-0","volume":"113","author":"L Fratiglioni","year":"2000","unstructured":"Fratiglioni L, Wang HX (2000) Smoking and Parkinson\u2019s and Alzheimer\u2019s disease: review of the epidemiological studies. Behavioural Brain Res 113:117\u2013120","journal-title":"Behavioural Brain Res"},{"key":"8031_CR194","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00702-006-0561-z","volume":"114","author":"G Mudo","year":"2007","unstructured":"Mudo G, Belluardo N, Fuxe K (2007) Nicotinic receptor agonists as neuroprotective\/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 114:135\u2013147","journal-title":"J Neural Transm"},{"key":"8031_CR195","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tips.2005.05.007","volume":"26","author":"JJ Buccafusco","year":"2005","unstructured":"Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM (2005) Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 26:352\u2013360","journal-title":"Trends Pharmacol Sci"},{"key":"8031_CR196","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0269881107066855","volume":"21","author":"GC Dunbar","year":"2007","unstructured":"Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J (2007) Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol (Oxford, England) 21:171\u2013178","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"8031_CR197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(06)78008-4","volume":"78","author":"LF Martin","year":"2007","unstructured":"Martin LF, Freedman R (2007) Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 78:225\u2013246","journal-title":"Int Rev Neurobiol"},{"key":"8031_CR198","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pharmthera.2005.05.001","volume":"108","author":"ES Mitchell","year":"2005","unstructured":"Mitchell ES, Neumaier JF (2005) 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 108:320\u2013333","journal-title":"Pharmacol Ther"},{"key":"8031_CR199","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.drudis.2006.02.004","volume":"11","author":"J Holenz","year":"2006","unstructured":"Holenz J, Pauwels PJ, Diaz JL, Merce R, Codony X, Buschmann H (2006) Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today 11:283\u2013299","journal-title":"Drug Discov Today"},{"key":"8031_CR200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1073858406296716","volume":"13","author":"Y Hashimotodani","year":"2007","unstructured":"Hashimotodani Y, Ohno-Shosaku T, Kano M (2007) Endocannabinoids and synaptic function in the CNS. Neuroscientist 13:127\u2013137","journal-title":"Neuroscientist"},{"key":"8031_CR201","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/sj.npp.1301297","volume":"32","author":"LE Wise","year":"2007","unstructured":"Wise LE, Iredale PA, Stokes RJ, Lichtman AH (2007) Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacology 32:1805\u20131812","journal-title":"Neuropsychopharmacology"},{"key":"8031_CR202","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/13543784.16.7.967","volume":"16","author":"M Wijtmans","year":"2007","unstructured":"Wijtmans M, Leurs R, de Esch I (2007) Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 16:967\u2013985","journal-title":"Expert Opin Investig Drugs"},{"key":"8031_CR203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1254\/jphs.CPJ06007X","volume":"100","author":"E Miyamoto","year":"2006","unstructured":"Miyamoto E (2006) Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci 100:433\u2013442","journal-title":"J Pharmacol Sci"},{"key":"8031_CR204","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2174\/138161205774370799","volume":"11","author":"GM Rose","year":"2005","unstructured":"Rose GM, Hopper A, De Vivo M, Tehim A (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11:3329\u20133334","journal-title":"Curr Pharm Des"},{"key":"8031_CR205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.neurobiolaging.2006.03.006","volume":"28","author":"GM Rose","year":"2007","unstructured":"Rose GM, Ong VS, Woodruff-Pak DS (2007) Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging 28:766\u2013773","journal-title":"Neurobiol Aging"},{"key":"8031_CR206","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/138945007780618490","volume":"8","author":"AC Arai","year":"2007","unstructured":"Arai AC, Kessler M (2007) Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Current Drug Targets 8:583\u2013602","journal-title":"Current Drug Targets"},{"key":"8031_CR207","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neuropharm.2006.04.018","volume":"51","author":"JR Atack","year":"2006","unstructured":"Atack JR, Bayley PJ, Seabrook GR, Wafford KA, McKernan RM, Dawson GR (2006) L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology 51:1023\u20131029","journal-title":"Neuropharmacology"},{"key":"8031_CR208","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coph.2005.10.002","volume":"6","author":"NG Bowery","year":"2006","unstructured":"Bowery NG (2006) GABAB receptor: a site of therapeutic benefit. Curr Opin Pharmacol 6:37\u201343","journal-title":"Curr Opin Pharmacol"},{"key":"8031_CR209","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O\u2019Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurology 6:734\u2013746","journal-title":"Lancet Neurology"},{"key":"8031_CR210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 5:228\u2013234","journal-title":"Lancet Neurology"},{"key":"8031_CR211","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","volume":"69","author":"JL Cummings","year":"2007","unstructured":"Cummings JL, Doody R, Clark C (2007) Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69:1622\u20131634","journal-title":"Neurology"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-008-8031-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-008-8031-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-008-8031-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:37:38Z","timestamp":1559443058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-008-8031-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":211,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["8031"],"URL":"https:\/\/doi.org\/10.1007\/s12035-008-8031-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}